- Home
- DHY vs BWAY Comparison
DHY vs BWAY Comparison
Compare DHY & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- BWAY
- Stock Information
- Founded
- DHY 1998
- BWAY 2003
- Country
- DHY United States
- BWAY Israel
- Employees
- DHY N/A
- BWAY N/A
- Industry
- DHY Finance/Investors Services
- BWAY Medical/Dental Instruments
- Sector
- DHY Finance
- BWAY Health Care
- Exchange
- DHY Nasdaq
- BWAY Nasdaq
- Market Cap
- DHY 211.3M
- BWAY 201.1M
- IPO Year
- DHY N/A
- BWAY 2019
- Fundamental
- Price
- DHY $2.13
- BWAY $13.24
- Analyst Decision
- DHY
- BWAY Strong Buy
- Analyst Count
- DHY 0
- BWAY 2
- Target Price
- DHY N/A
- BWAY $14.25
- AVG Volume (30 Days)
- DHY 569.1K
- BWAY 53.5K
- Earning Date
- DHY 01-01-0001
- BWAY 08-05-2025
- Dividend Yield
- DHY 9.10%
- BWAY N/A
- EPS Growth
- DHY N/A
- BWAY N/A
- EPS
- DHY N/A
- BWAY 0.08
- Revenue
- DHY N/A
- BWAY $43,457,000.00
- Revenue This Year
- DHY N/A
- BWAY $351.53
- Revenue Next Year
- DHY N/A
- BWAY $21.84
- P/E Ratio
- DHY N/A
- BWAY $63.96
- Revenue Growth
- DHY N/A
- BWAY 26.86
- 52 Week Low
- DHY $1.77
- BWAY $5.67
- 52 Week High
- DHY $2.08
- BWAY $13.35
- Technical
- Relative Strength Index (RSI)
- DHY 74.31
- BWAY 72.01
- Support Level
- DHY $2.12
- BWAY $12.60
- Resistance Level
- DHY $2.00
- BWAY $13.35
- Average True Range (ATR)
- DHY 0.02
- BWAY 0.48
- MACD
- DHY 0.00
- BWAY 0.11
- Stochastic Oscillator
- DHY 88.89
- BWAY 94.81
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.